{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T20:43:25Z","timestamp":1788468205760,"version":"build-2803163510"},"reference-count":34,"publisher":"BMJ","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"the Capital\u2019s Funds for Health Improvement and Research","award":["CFH2024-2-2045"],"award-info":[{"award-number":["CFH2024-2-2045"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Stroke Vasc Neurol"],"accepted":{"date-parts":[[2026,1,20]]},"abstract":"<jats:sec>\n                    <jats:title>Background and purpose<\/jats:title>\n                    <jats:p>Evidence on whether add-on early antiplatelet therapy may improve functional outcome in acute ischaemic stroke (AIS) patients treated with intravenous thrombolysis (IVT) remains inconsistent. This study aims to evaluate the efficacy and safety of oral ticagrelor plus aspirin within 6\u2009hours of symptom onset in IVT-treated AIS patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and design<\/jats:title>\n                    <jats:p>Efficacy and Safety of Ticagrelor with Aspirin Dual Antiplatelet Therapy Combined with Intravenous Thrombolysis in Patients with Ischemic Stroke (TAPIS) is a multicentre, randomised, double-blind, parallel-group, placebo-controlled trial. The study will enrol 1380 AIS patients with a pre-IVT National Institutes of Health Stroke Scale (NIHSS) score of 4\u201310 who have received\/are intended to receive IVT with alteplase or tenecteplase within 4.5\u2009hours of onset. Eligible participants will be randomised at a 1:1 ratio within 6\u2009hours of onset, before, during or after IVT. The intervention group will receive a loading dose of ticagrelor tablets (180\u2009mg) and aspirin tablets (100\u2009mg) on day 1, and ticagrelor (90\u2009mg two times per day) plus open-label aspirin (100\u2009mg daily) for days 2\u20137. The control group will receive ticagrelor placebo and aspirin placebo on day 1, and ticagrelor placebo plus open-label aspirin for days 2\u20137. Both groups will receive open-label aspirin (100\u2009mg daily) for days 8\u201390.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study outcomes<\/jats:title>\n                    <jats:p>The primary efficacy outcome is excellent functional outcome at 90 days, defined as a modified Rankin Scale (mRS) score of 0\u20131. Secondary efficacy outcomes include mRS score of 0\u20132 at 90 days, distribution of mRS scores at 90 days, NIHSS score at 7\u2009days decreasing by \u22654 points from baseline and recurrent ischaemic stroke within 90 days. The primary safety outcome is symptomatic intracerebral haemorrhage within 36 hours.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This trial will evaluate whether early dual antiplatelet therapy with ticagrelor plus aspirin could improve functional outcomes of IVT-treated AIS patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06316570\">NCT06316570<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/svn-2025-004721","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T14:35:18Z","timestamp":1769697318000},"page":"svn-2025-004721","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Rationale and design of Ticagrelor with Aspirin Dual Antiplatelet Therapy Combined with Intravenous Thrombolysis in Patients with Ischemic Stroke (TAPIS): a multicentre, randomised, double-blind, parallel group, placebo-controlled trial"],"prefix":"10.1136","clinical-trial-number":[{"clinical-trial-number":"nct06316570","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4351-2877","authenticated-orcid":false,"given":"Anxin","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"Department of Clinical Epidemiology and Clinical Trial, Capital Medical University, Beijing, China"},{"name":"Department of Epidemiology, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1719-0598","authenticated-orcid":false,"given":"Xue","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"Department of Clinical Epidemiology and Clinical Trial, Capital Medical University, Beijing, China"},{"name":"Department of Epidemiology, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2734-5132","authenticated-orcid":false,"given":"Philip M","family":"Bath","sequence":"additional","affiliation":[{"name":"Stroke Trials Unit, Mental Health & Clinical Neuroscience, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Turc","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Institute of Psychiatry and Neurosciences of Paris (IPNP), INSERM U1266, Paris, France"},{"name":"Department of Neurology, GHU Paris Psychiatrie et Neurosciences, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"Department of Epidemiology, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"Department of Epidemiology, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3267-0039","authenticated-orcid":false,"given":"Yilong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"Chinese Institute for Brain Research, Beijing, China"},{"name":"National Center for Neurological Disorders, Beijing, China"},{"name":"Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"2026012906350932000_svn-2025-004721v1.1","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","article-title":"Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"403","author":"Ferrari","year":"2024","journal-title":"The Lancet"},{"key":"2026012906350932000_svn-2025-004721v1.2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.110.606194"},{"key":"2026012906350932000_svn-2025-004721v1.3","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000258112.14918.24"},{"key":"2026012906350932000_svn-2025-004721v1.4","doi-asserted-by":"crossref","first-page":"I","DOI":"10.1177\/2396987321989865","article-title":"European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke","volume":"6","author":"Berge","year":"2021","journal-title":"Eur Stroke J"},{"key":"2026012906350932000_svn-2025-004721v1.5","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.119.027708"},{"key":"2026012906350932000_svn-2025-004721v1.6","first-page":"1461","article-title":"Chinese Stroke Association, Writing Group of Chinese Stroke Association Guidelines on Reperfusion Therapy for Acute Ischemic Stroke 2024.Chinese Stroke Association Guidelines on Reperfusion Therapy for Acute Ischemic Stroke 2024","volume":"19","year":"2024","journal-title":"Chinese Journal of Stroke"},{"key":"2026012906350932000_svn-2025-004721v1.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0804656"},{"key":"2026012906350932000_svn-2025-004721v1.8","first-page":"923","article-title":"Platelet activation by fibrinolytic agents: a potential mechanism for resistance to thrombolysis and reocclusion after successful thrombolysis","volume":"6","author":"Leopold","year":"1995","journal-title":"Coron Artery Dis"},{"key":"2026012906350932000_svn-2025-004721v1.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512143332401"},{"key":"2026012906350932000_svn-2025-004721v1.10","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S0140-6736(95)92049-8","article-title":"Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke","volume":"346","year":"1995","journal-title":"The Lancet"},{"key":"2026012906350932000_svn-2025-004721v1.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60949-0"},{"key":"2026012906350932000_svn-2025-004721v1.12","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.32.3.661"},{"key":"2026012906350932000_svn-2025-004721v1.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1747-4949.2009.00331.x"},{"key":"2026012906350932000_svn-2025-004721v1.14","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.113.001059"},{"key":"2026012906350932000_svn-2025-004721v1.15","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.115.010260"},{"key":"2026012906350932000_svn-2025-004721v1.16","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.108.517656"},{"key":"2026012906350932000_svn-2025-004721v1.17","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.119.026240"},{"key":"2026012906350932000_svn-2025-004721v1.18","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2503678","article-title":"Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke","volume":"393","author":"Tao","year":"2025","journal-title":"N Engl J Med"},{"key":"2026012906350932000_svn-2025-004721v1.19","doi-asserted-by":"crossref","unstructured":"Chen H-S , Cui Y , Li X-Q , et al . Early antiplatelet treatment for minor stroke following thrombolysis: the EAST trial. Eur Heart J 2025.:ehaf702. doi:10.1093\/eurheartj\/ehaf702","DOI":"10.1093\/eurheartj\/ehaf702"},{"key":"2026012906350932000_svn-2025-004721v1.20","first-page":"666","article-title":"Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018","volume":"51","year":"2018","journal-title":"Chinese Journal of Neurology"},{"key":"2026012906350932000_svn-2025-004721v1.21","first-page":"523","article-title":"Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2023","volume":"57","year":"2024","journal-title":"Chinese Journal of Neurology"},{"key":"2026012906350932000_svn-2025-004721v1.22","doi-asserted-by":"publisher","DOI":"10.1161\/strokeaha.121.034480"},{"key":"2026012906350932000_svn-2025-004721v1.23","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.109.571562"},{"key":"2026012906350932000_svn-2025-004721v1.24","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.111.613273"},{"key":"2026012906350932000_svn-2025-004721v1.25","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(24)00139-9","article-title":"Recommendations for accurate reporting in medical research statistics","volume":"403","author":"Mansournia","year":"2024","journal-title":"Lancet"},{"key":"2026012906350932000_svn-2025-004721v1.26","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1212\/WNL.59.6.862","article-title":"Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator","volume":"59","author":"Alexandrov","year":"2002","journal-title":"Neurology (ECronicon)"},{"key":"2026012906350932000_svn-2025-004721v1.27","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000251800.01964.f6"},{"key":"2026012906350932000_svn-2025-004721v1.28","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000170711.43405.81"},{"key":"2026012906350932000_svn-2025-004721v1.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60584-5"},{"key":"2026012906350932000_svn-2025-004721v1.30","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1177\/17474930221118900","article-title":"Early antiplatelet for minor stroke following thrombolysis (EAST): Rationale and design","volume":"18","author":"Li","year":"2023","journal-title":"Int J Stroke"},{"key":"2026012906350932000_svn-2025-004721v1.31","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.116.013105"},{"key":"2026012906350932000_svn-2025-004721v1.32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.12584"},{"key":"2026012906350932000_svn-2025-004721v1.33","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.024913"},{"key":"2026012906350932000_svn-2025-004721v1.34","first-page":"e46","article-title":"Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack","volume":"99","author":"Wang","year":"2022","journal-title":"Neurology (ECronicon)"}],"container-title":["Stroke and Vascular Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/svn-2025-004721","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T14:35:20Z","timestamp":1769697320000},"score":1,"resource":{"primary":{"URL":"https:\/\/svn.bmj.com\/lookup\/doi\/10.1136\/svn-2025-004721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":34,"alternative-id":["10.1136\/svn-2025-004721"],"URL":"https:\/\/doi.org\/10.1136\/svn-2025-004721","relation":{},"ISSN":["2059-8688","2059-8696"],"issn-type":[{"value":"2059-8688","type":"print"},{"value":"2059-8696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]}}}